Cost Effectiveness of Ceftolozane/Tazobactam Compared With Meropenem for the Treatment of Patients With Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
figureposted on 06.04.2021, 16:43 by Adis journals on behalf of, Jaesh Naik, Laura Puzniak, Simone Critchlow, David Elsea, Ryan James Dillon, Joe Yang
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.